Treatment of complex periorbital venolymphatic malformation in a neonate with a combination therapy of sirolimus and prednisolone

Dermatologic Therapy

Volumn 28, Issue 4, 2015, Pages 218-221

  Kim, David ^a   Benjamin, Latanya ^a   Wysong, Ashley ^a   Hovsepian, David ^a   Teng, Joyce ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

prednisolone; sirolimus; vascular malformation; venolymphatic malformation

Indexed keywords

COTRIMOXAZOLE; MONOCLONAL ANTIBODY D2-40; PREDNISOLONE; RAPAMYCIN; SILDENAFIL; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ADD ON THERAPY; AMBLYOPIA; ARTICLE; CASE REPORT; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXOPHTHALMOS; FEMALE; FOLLOW UP; FOREHEAD; GENETIC SCREENING; HISPANIC; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LYMPHATIC MALFORMATION; NEWBORN; NEWBORN DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBIT; ORBIT DISEASE; PAPULE; PERIORBITAL EDEMA; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE INFLAMMATION; PULMONARY HYPERTENSION; RESPIRATORY TRACT INTUBATION; SCALP; SCLEROTHERAPY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; VAGINAL DELIVERY; VENOLYMPHATIC MALFORMATION; VISUAL IMPAIRMENT; COMBINATION DRUG THERAPY; EYE; LYMPHATIC ABNORMALITIES; PROCEDURES; RECURRENT DISEASE; RETREATMENT; VASCULAR MALFORMATIONS;

ANTI-INFLAMMATORY AGENTS; DRUG THERAPY, COMBINATION; EYE; FEMALE; FOREHEAD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; LYMPHATIC ABNORMALITIES; PREDNISOLONE; RECURRENCE; RETREATMENT; SIROLIMUS; VASCULAR MALFORMATIONS;

EID: 84937728539     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12208     Document Type: Article

References (14)

1. Dompmartin A, Acher A, Thibon P, et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol 2008: 144 (7): 873-877.
2. Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011: 57 (6): 1018-1024.
3. Patel DV,. Gorham's disease or massive osteolysis. Clin Med Res 2005: 3 (2): 65-74.
4. Swetman GL, Berk DR, Vasanawala SS, et al. Sildenafil for severe lymphatic malformations. N Engl J Med 2012: 366 (4): 384-386.
5. Blatt J, Stavas J, Moats-Staats B, et al. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 2010: 55 (7): 1396-1398.
6. Greenberger S, Yuan S, Walsh LA, et al. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J Invest Dermatol 2011: 131 (12): 2467-2476.
7. Lee BB, Do YS, Byun HS, et al. Advanced management of venous malformation with ethanol sclerotherapy: mid-term results. J Vasc Surg 2003: 37 (3): 533-538.
8. Hammer FD, Boon LM, Mathurin P, et al. Ethanol sclerotherapy of venous malformations: evaluation of systemic ethanol contamination. J Vasc Interv Radiol 2001: 12 (5): 595-600.
9. Zhang J, Li HB, Zhou SY, et al. Comparison between absolute ethanol and bleomycin for the treatment of venous malformation in children. Exp Ther Med 2013: 6 (2): 305-309.
10. Ierardi AM, Mangini M, Vaghi M, et al. Sclerotherapy of peripheral venous malformations: a new technique to prevent serious complications. Vasc Endovascular Surg 2010: 44 (4): 282-288.
11. Cahill AM, Nijs E, Ballah D, et al. Percutaneous sclerotherapy in neonatal and infant head and neck lymphatic malformations: a single center experience. J Pediatr Surg 2011: 46 (11): 2083-2095.
12. Kobayashi S, Kishimoto T, Kamata S, et al. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 2007: 98 (5): 726-733.
13. Makinen T, Veikkola T, Mustjoki S, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 2001: 20 (17): 4762-4773.
14. Salameh A, Galvagni F, Bardelli M, et al. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood 2005: 106 (10): 3423-3431.